CMKLR1 and cancer: In conclusion, in line with previous reports demonstrating the therapeutic interest to promote inflammation resolution during cancer treatments, our results also argue that targeting ChemR23 using an agonist antibody may improve cancer evolution in limiting metastasis occurrence.